

SECURITIES AND EXCHANGE COMMISSION

FORM 8-K

Current report filing

Filing Date: **2006-08-03** | Period of Report: **2006-08-02**
SEC Accession No. **0001157523-06-007867**

([HTML Version](#) on [secdatabase.com](#))

FILER

Advanced BioPhotonics Inc.

CIK: **1096182** | IRS No.: **841209909** | State of Incorporation: **DE** | Fiscal Year End: **1231**
Type: **8-K** | Act: **34** | File No.: **000-27943** | Film No.: **061000024**
SIC: **3829** Measuring & controlling devices, nec

Mailing Address

12-8 TECHNOLOGY DRIVE
EAST SETANKET NY 11733

Business Address

12-8 TECHNOLOGY DRIVE
EAST SETANKET NY 11733
631-689-3781

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of report (Date of earliest event reported): August 2, 2006

ADVANCED BIOPHOTONICS INC.
(Exact Name of Registrant as Specified in Charter)

Delaware (State or other jurisdiction of incorporation)	0-27943 (Commission File Number)	11-3386214 (IRS Employer Identification No.)
---	-------------------------------------	--

125 Wilbur Place, Suite 120 Bohemia, New York (Address of principal executive offices)	11716 (Zip Code)
--	---------------------

Registrant's telephone number, including area code: (631) 244-8244

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 DFR 240.14a-12)

[] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[] Pre-commencement communications pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01 Entry into a Material Definitive Agreement.

On August 2, 2006, Advanced BioPhotonics Inc. (the "Company") entered into a Pilot Site Research Agreement with Beth Israel Deaconess Medical Center (BIDMC), a teaching hospital of Harvard Medical School, under which BIDMC will conduct clinical trials using the Company's patented BioScanIR(R) System, together with its proprietary DIRI(R) dynamic infrared imaging software platform in a reconstructive surgery application. Under the clinical trial protocol, BIDMC will use the Company's BioScanIR(R) System and DIRI(R) software to collect and interpret data relating to locating the perforator vessels in vivo.

On August 3, 2006, the Company issued a press release announcing the agreement with BIDMC to conduct a clinical trial using the Company's BioScanIR(R) System and DIRI(R) dynamic infrared imaging software platform. A copy of this press release has been filed with this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits

Exhibit Number	Description
-----	-----
99.1	Press Release Dated August 3, 2006

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ADVANCED BIOPHOTONICS INC.

Date: August 3, 2006

By: /s/ Denis A. O'Connor

Denis A. O'Connor
President and Chief Executive Officer

Advanced BioPhotonics Inc. and Harvard's Beth Israel Deaconess Medical
Center Enter Into Pilot Research Agreement

BOHEMIA, N.Y.--(BUSINESS WIRE)--Aug. 3, 2006--Advanced
BioPhotonics Inc. (OTCBB: ABPH):

-- Beth Israel Deaconess Medical Center To Serve As The Fourth
Pilot Research Site To Investigate The Unique Use Of Company's
DIRI(R) Technology In Identifying Perforator Vessels In
Plastic And Reconstructive Surgery Procedures

Advanced BioPhotonics Inc. (OTCBB: ABPH) a developer of next
generation medical imaging applications using advanced infrared
technology announced today that it has entered into an agreement with
Beth Israel Deaconess Medical Center (BIDMC), a teaching hospital of
Harvard Medical School. BIDMC will participate in the Company's
multi-center clinical trial investigating the use of Advanced
BioPhotonics' proprietary DIRI(R) method of dynamic infrared imaging
in mapping vascular perforator blood vessels in Plastic and
Reconstructive Surgery procedures.

"Beth Israel Deaconess Medical Center is the fourth and final
luminary medical center to join this multi-center trial," said Robert
P. Ellis, Senior Vice President, Advanced BioPhotonics. "We continue
to generate excitement and make steady progress in this plastic
surgery application. Based on earlier work, our technology holds the
promise of shortening procedure times and improving flap viability. We
are honored to have a Harvard teaching site such as BIDMC participate
and we continue to demonstrate our technology in this important
clinical trial."

To conduct this study, which is scheduled to begin within two
weeks, BIDMC will utilize the Company's patented BioScanIR(R) System,
a dynamic infrared imaging modality. The BioScanIR(R) provides a fast,
non-invasive, radiation-free method for detecting diseases that affect
perfusion, and reperfusion in human tissue. The agreement is for a
period of one year.

"We are excited about collaborating with Advanced BioPhotonics,"
said Loren J. Borud, M.D., a plastic surgeon and principal
investigator at BIDMC. "We believe this technology could become a
major tool for us in planning and safely executing a broad range of
flap procedures, from breast reconstruction to body contouring."

The Company expects to conclude the trial in September 2006 in
preparation for commercial release of a reconstructive surgery
application in the fourth quarter of 2006.

"We are working with four very prestigious medical institutions,
with leading surgeons in the field of reconstructive surgery" said
Denis A. O'Connor, CEO of Advanced BioPhotonics. "We are looking
forward to completing this clinical trial and to debut our

reconstructive surgery application at the American Society of Plastic Surgery Conference in early October".

About Advanced BioPhotonics

Advanced BioPhotonics Inc. (OTCBB: ABPH) headquartered in Bohemia, New York, is an innovative developer of medical imaging applications using advanced infrared technology. Advanced BioPhotonics provides imaging technology for clinicians and researchers for use in the detection and management of diseases affecting perfusion or reperfusion of tissue or organs.

Advanced BioPhotonics's mission is to improve the quality and cost-effectiveness of healthcare services and research through identifying, acquiring and adapting high-resolution infrared technology for biomedical applications. For more information about the Company and its technology, please visit <http://www.advancedbp.com/>.

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe", "estimate", "project", "expect" or similar expressions. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company's products and services in the marketplace, the ability of the Company to develop effective new products and receive governmental approvals of such products, competitive factors, dependence upon third-party vendors, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.

CONTACT: Advanced BioPhotonics Inc.
Denis O'Connor, 631-244-8244
doconnor@advancedbp.com
or
Robert P. Ellis, 631-244-8244
rellis@advancedbp.com
or
Investors:
The Investor Relations Group
Erika Moran or Tom Caden, 212-825-3210